Catalyst Wire Dossier Catalyst Wire Dossier

Lutetium-177 vipivotide tetraxetan (AAA617)

lutetium-177 vipivotide tetraxetan · Novartis Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Lutetium-177 vipivotide tetraxetan (AAA617), covering 2026-04-08 to 2026-04-08. Get the full timeline:

Most recent: Clinical Trial Update: An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC [Phase 2]

See pricing